On the Discovery of TOR As the Target of Rapamycin

The National Institutes of Health (NIH) launched the medical scientist training program in 1964 to train physician-scientists as ambassadors between the disparate worlds of science and medicine. Scientists at this company discovered and developed cyclosporin as the gold-standard drug for organ tra...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PLoS pathogens 2015-11, Vol.11 (11), p.e1005245-e1005245
1. Verfasser:	Heitman, Joseph
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Anti-Bacterial Agents - therapeutic use Brewer's yeast Chemotherapy Drugs Funding Health aspects Humans Immunosuppressive Agents - therapeutic use Kinases Mammals Medical schools Physiological aspects Proteins Rapamycin Research Matters Scientists Sirolimus - therapeutic use Studies TOR Serine-Threonine Kinases - drug effects Transplants Transplants & implants Vaccines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The National Institutes of Health (NIH) launched the medical scientist training program in 1964 to train physician-scientists as ambassadors between the disparate worlds of science and medicine. Scientists at this company discovered and developed cyclosporin as the gold-standard drug for organ transplant patients.
ISSN:	1553-7374 1553-7366 1553-7374
DOI:	10.1371/journal.ppat.1005245